
Biotech group Oxford Nanopore Technologies ONT.L up as much as 5.7% at 115.9p
Gene sequencing specialist is now "exposed" to acquisition, CEO and co-founder Gordon Sanghera told FT
ONT's shares have lost 85% since its peak in 2021
"Bankers have said it could be attractive to one of the big diagnostics specialists, such as Thermo Fisher Scientific TMO.N or Danaher DHR.N," FT report adds
As of last close, stock down ~15% this year